Kronox Lab Sciences Ltd. Fundamental Analysis (NSE: KRONOX.NS)
Kronox Lab Sciences Ltd. Fundamental Analysis (NSE: KRONOX.NS)
Kronox Lab Sciences Ltd. (NSE: KRONOX.NS) shows moderate financial fundamentals with a PE ratio of 27.80, profit margin of 27.13%, and ROE of 27.94%. The company generates $1.1B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 84.9/100 based on profitability, valuation, growth, and balance sheet metrics. The B+ grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze KRONOX.NS's fundamental strength across five key dimensions:
Efficiency Score
ExcellentKRONOX.NS demonstrates superior asset utilization.
Valuation Score
WeakKRONOX.NS trades at a premium to fair value.
Growth Score
ModerateKRONOX.NS shows steady but slowing expansion.
Financial Health Score
ExcellentKRONOX.NS maintains a strong and stable balance sheet.
Profitability Score
ExcellentKRONOX.NS achieves industry-leading margins.
Key Financial Metrics
Is KRONOX.NS Expensive or Cheap?
P/E Ratio
KRONOX.NS trades at 27.80 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, KRONOX.NS's PEG of 2.41 indicates potential overvaluation.
Price to Book
The market values Kronox Lab Sciences Ltd. at 6.88 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 20.24 times EBITDA. This signals the market has high growth expectations.
How Well Does KRONOX.NS Make Money?
Net Profit Margin
For every $100 in sales, Kronox Lab Sciences Ltd. keeps $27.13 as profit after all expenses.
Operating Margin
Core operations generate 31.42 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $27.94 in profit for every $100 of shareholder equity.
ROA
Kronox Lab Sciences Ltd. generates $22.40 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Kronox Lab Sciences Ltd. generates limited operating cash flow of $104.97M, signaling weaker underlying cash strength.
Free Cash Flow
Kronox Lab Sciences Ltd. produces free cash flow of $74.67M, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $2.01 in free cash annually.
FCF Yield
KRONOX.NS converts 0.94% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
27.80
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
2.41
vs 25 benchmark
P/B Ratio
Price to book value ratio
6.88
vs 25 benchmark
P/S Ratio
Price to sales ratio
7.58
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.01
vs 25 benchmark
Current Ratio
Current assets to current liabilities
7.60
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.28
vs 25 benchmark
ROA
Return on assets percentage
0.22
vs 25 benchmark
ROCE
Return on capital employed
0.28
vs 25 benchmark
How KRONOX.NS Stacks Against Its Sector Peers
| Metric | KRONOX.NS Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 27.80 | 27.37 | Neutral |
| ROE | 27.94% | 1190.00% | Weak |
| Net Margin | 27.13% | 204.00% | Weak |
| Debt/Equity | 0.01 | 0.73 | Strong (Low Leverage) |
| Current Ratio | 7.60 | 3.14 | Strong Liquidity |
| ROA | 22.40% | 2758.00% | Weak |
KRONOX.NS outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Kronox Lab Sciences Ltd.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Cyclical, Commodity, Value
EPS CAGR
N/A
Industry Style: Cyclical, Commodity, Value
FCF CAGR
N/A
Industry Style: Cyclical, Commodity, Value